Shares of biotechnology company PepGen (NASDAQ:PEPG) are up in the pre-market session today after its lead candidate PGN-ED051 demonstrated promising results in a Phase 1 trial for treating Duchenne Muscular Dystrophy (DMD).
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
The drug showed high oligonucleotide delivery and exon skipping and was generally well tolerated. The company now plans to begin a Phase 2a trial in the first half of 2023.
Is PEPG Stock a Buy?
Analysts currently have a Strong Buy consensus rating on PEPG stock with an average price target of $27 which indicates a massive 227.27% potential upside for PepGen Stock.

Read full Disclosure